CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 11 enrolled
Drug / intervention
Laboratory Biomarker Analysis +2 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02830165
NCT02830165N/ACompleted

Phase I Feasibility Trial of Preoperative Adjuvant Stereotactic Body Radiotherapy for Patients at High Risk of Local Failure After Prostatectomy

Jonsson Comprehensive Cancer Center·interventional·Posted Jul 12, 2016·Updated May 23, 2024

In Brief

A clinical study evaluating Laboratory Biomarker Analysis, Quality-of-Life Assessment, and 1 other intervention for Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7 and 2 related conditions. Completed, enrolled 11 participants across 1 site.

Detailed Summary

This phase I trial studies stereotactic body radiation therapy (SBRT) in treating patients with prostate cancer that is likely to come back or spread (high-risk) undergoing surgery. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Delivering radiotherapy before prostatectomy by SBRT is more convenient, conformal, and may spare normal tissues better than delivering radiotherapy after prostatectomy.

Study Details

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJul 12, 2016
Enrollment StartJun 15, 2016
Primary CompletionMay 9, 2020
Study CompletionMay 27, 2022
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 10.0 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Quality-of-Life Assessmentother

Ancillary studies

Stereotactic Body Radiation Therapyradiation

Undergo SBRT